Showing 2441-2450 of 3199 results for "".
Business Advisor: Mapping Out a Price/Benefit Value Strategy for Your Practice
https://practicaldermatology.com/topics/general-topics/business-advisor-mapping-out-a-pricebenefit-value-strategy-for-your-practice/22043/Using a Price/Benefit map is a good way for practices to set prices and plan to adapt to changing markets.The Hidradenitis Suppurativa Therapeutic Pipeline
https://practicaldermatology.com/topics/rare-disease/the-hidradenitis-suppurativa-therapeutic-pipeline/54824/Though treatment options are currently limited, the pipeline for HS therapeutics is active with numerous medications in development.10 Procedural Tips for Hidradenitis Suppurativa
https://practicaldermatology.com/topics/rare-disease/10-procedural-tips-for-hidradenitis-suppurativa/56430/This guide was created to assist dermatologists who care for patients with HS considering surgery and emphasizes the importance of patient-centered care, expectation setting, and advanced surgical techniques.Apocrine Hidrocystoma of the Axilla
https://practicaldermatology.com/issues/october-2025/apocrine-hidrocystoma-of-the-axilla-an-illustrative-case-and-literature-review/39757/An Illustrative Case and Literature ReviewPreparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuDermatology Recruitment in the Age of Private Equity
https://practicaldermatology.com/issues/september-2025/dermatology-recruitment-in-the-age-of-private-equity/37638/A recruiting executive offers a balanced view from the fieldComorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.Journal Club: Dupilumab and Atopic March
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-dupilumab-and-atopic-march/32405/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Peter Lio, MD, discuss recent research indicating a reduced risk of atopic march in pediatric atopic dermatitis patients on dupilumab.Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. ReducedJournal Club: Biologics for Young Children
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-biologics-for-young-children/32400/Practical Dermatology Editorial Board member Lawrence Eichenfield, MD, FAAD, Dawn Eichenfield, MD, PhD, discuss the article "Biologic therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations," from Expert Opinion on Drug Safety. R